Tags

Type your tag names separated by a space and hit enter

[Capecitabine-induced subacute cutaneous lupus: a case report].
Ann Dermatol Venereol. 2014 Oct; 141(10):593-7.AD

Abstract

BACKGROUND

More than 100 drugs have been registered as inducing subacute cutaneous lupus erythematosus (SCLE). Recently, some types of chemotherapy have also been incriminated. If SCLE develops in a setting of neoplasia, two possibilities should be considered: it is either a paraneoplastic syndrome or it is caused by the chemotherapy, thus calling for important decisions on the benefit/risk of stopping potentially effective medication. We report a case of SCLE induced by Xeloda (capecitabine).

PATIENTS AND METHODS

A 50-year-old female patient consulted with an annular erythematosquamous and pruriginous eruption, predominantly on areas of the body exposed to sunlight, occurring 4 months after the initiation of capecitabine for advanced colon cancer. She had presented systemic lupus erythematosus (SLE) for many years, which was not treated, was not progressive and had no cutaneous manifestations. The appearance of the cutaneous lesions, positivity for anti-SSA antibodies and the histological aspect led to diagnosis of SCLE. The lesions were resistant to treatment with hydroxychloroquine and systemic corticosteroids, but disappeared after discontinuation of capecitabine, suggesting chemotherapy-induced SCLE.

DISCUSSION

Some types of chemotherapy such as capecitabine may reveal or induce SCLE lesions, whether or not there is a previous history of SLE. Cases of chemotherapy-induced cutaneous lupus reported to the French pharmacovigilance agency are rare, but this side effect must be recognised due to the constantly rising use of this type of anticancer agent.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Fongue J
Service de dermatologie, CHU La Timone, 13005 Marseille, France; Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France.
Meunier B
Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France.
Lardet D
Cabinet de dermatologie, 47B, avenue Maréchal-Foch, 83390 Cuers, France.
Dicostanzo MP
Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France.
Rouby F
Pharmacovigilance, hôpital Salvator, 13009 Marseille, France.
Terrier JP
Laboratoire d'anatomopathologie, 219, rue Revel, 83000 Toulon, France.
Harlé JR
Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France.
Richard MA
Service de dermatologie, CHU La Timone, 13005 Marseille, France.
Chiche L
Service de médecine interne, centre de compétence PACA Ouest pour la prise en charge des pathologies auto-immunes systémiques, CHU de la Conception, 147, boulevard Baille, 13005 Marseille, France. Electronic address: laurent.chiche@ap-hm.fr.

MeSH

Adverse Drug Reaction Reporting SystemsAntimetabolites, AntineoplasticCapecitabineColonic NeoplasmsDeoxycytidineDiagnosis, DifferentialFemaleFluorouracilFranceHumansLupus Erythematosus, CutaneousMiddle Aged

Pub Type(s)

Case Reports
English Abstract
Journal Article

Language

fre

PubMed ID

25288062

Citation

Fongue, J, et al. "[Capecitabine-induced Subacute Cutaneous Lupus: a Case Report]." Annales De Dermatologie Et De Venereologie, vol. 141, no. 10, 2014, pp. 593-7.
Fongue J, Meunier B, Lardet D, et al. [Capecitabine-induced subacute cutaneous lupus: a case report]. Ann Dermatol Venereol. 2014;141(10):593-7.
Fongue, J., Meunier, B., Lardet, D., Dicostanzo, M. P., Rouby, F., Terrier, J. P., Harlé, J. R., Richard, M. A., & Chiche, L. (2014). [Capecitabine-induced subacute cutaneous lupus: a case report]. Annales De Dermatologie Et De Venereologie, 141(10), 593-7. https://doi.org/10.1016/j.annder.2014.06.011
Fongue J, et al. [Capecitabine-induced Subacute Cutaneous Lupus: a Case Report]. Ann Dermatol Venereol. 2014;141(10):593-7. PubMed PMID: 25288062.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Capecitabine-induced subacute cutaneous lupus: a case report]. AU - Fongue,J, AU - Meunier,B, AU - Lardet,D, AU - Dicostanzo,M-P, AU - Rouby,F, AU - Terrier,J-P, AU - Harlé,J-R, AU - Richard,M-A, AU - Chiche,L, Y1 - 2014/08/06/ PY - 2014/02/11/received PY - 2014/04/08/revised PY - 2014/06/19/accepted PY - 2014/10/8/entrez PY - 2014/10/8/pubmed PY - 2015/6/24/medline KW - Capecitabine KW - Capécitabine KW - Chemotherapy KW - Chimiothérapie KW - Induced cutaneous lupus erythematosus KW - Lupus cutané induit KW - Lupus érythémateux subaigu KW - Subacute cutaneous lupus erythematosus SP - 593 EP - 7 JF - Annales de dermatologie et de venereologie JO - Ann Dermatol Venereol VL - 141 IS - 10 N2 - BACKGROUND: More than 100 drugs have been registered as inducing subacute cutaneous lupus erythematosus (SCLE). Recently, some types of chemotherapy have also been incriminated. If SCLE develops in a setting of neoplasia, two possibilities should be considered: it is either a paraneoplastic syndrome or it is caused by the chemotherapy, thus calling for important decisions on the benefit/risk of stopping potentially effective medication. We report a case of SCLE induced by Xeloda (capecitabine). PATIENTS AND METHODS: A 50-year-old female patient consulted with an annular erythematosquamous and pruriginous eruption, predominantly on areas of the body exposed to sunlight, occurring 4 months after the initiation of capecitabine for advanced colon cancer. She had presented systemic lupus erythematosus (SLE) for many years, which was not treated, was not progressive and had no cutaneous manifestations. The appearance of the cutaneous lesions, positivity for anti-SSA antibodies and the histological aspect led to diagnosis of SCLE. The lesions were resistant to treatment with hydroxychloroquine and systemic corticosteroids, but disappeared after discontinuation of capecitabine, suggesting chemotherapy-induced SCLE. DISCUSSION: Some types of chemotherapy such as capecitabine may reveal or induce SCLE lesions, whether or not there is a previous history of SLE. Cases of chemotherapy-induced cutaneous lupus reported to the French pharmacovigilance agency are rare, but this side effect must be recognised due to the constantly rising use of this type of anticancer agent. SN - 0151-9638 UR - https://www.unboundmedicine.com/medline/citation/25288062/[Capecitabine_induced_subacute_cutaneous_lupus:_a_case_report]_ DB - PRIME DP - Unbound Medicine ER -